+

WO1999042127A3 - Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs - Google Patents

Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs Download PDF

Info

Publication number
WO1999042127A3
WO1999042127A3 PCT/US1999/003910 US9903910W WO9942127A3 WO 1999042127 A3 WO1999042127 A3 WO 1999042127A3 US 9903910 W US9903910 W US 9903910W WO 9942127 A3 WO9942127 A3 WO 9942127A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
modulators
oligopeptides
derived peptides
modified
Prior art date
Application number
PCT/US1999/003910
Other languages
English (en)
Other versions
WO1999042127A2 (fr
Inventor
Lennart Olsson
Tatjana Naranda
Original Assignee
Receptron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptron Inc filed Critical Receptron Inc
Priority to JP2000532141A priority Critical patent/JP2002508160A/ja
Priority to AU27830/99A priority patent/AU2783099A/en
Priority to EP99908383A priority patent/EP1064015A2/fr
Priority to CA002322200A priority patent/CA2322200A1/fr
Publication of WO1999042127A2 publication Critical patent/WO1999042127A2/fr
Publication of WO1999042127A3 publication Critical patent/WO1999042127A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des oligopeptides dont la séquence d'acides aminés correspond à un domaine extracellulaire de récepteur et qui présentent une analogie de séquence avec des peptides régulateurs d'antigènes MHC de classe I. Ces peptides favorisent ou remplacent la réponse physiologique d'un ligand se liant avec le récepteur correspondant. Ces oligopeptides sont utilisés dans le diagnostic et le traitement de maladies en rapport avec une réponse insuffisante ou inappropriée des récepteurs, ainsi que pour le criblage de médicaments candidats qui ont une incidence sur l'expression de surface des récepteurs. Une molécule réceptrice modifiée, dont la séquence correspondant au peptide régulateur a été modifiée ou supprimée, convient également pour le criblage de médicaments.
PCT/US1999/003910 1998-02-24 1999-02-23 Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs WO1999042127A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000532141A JP2002508160A (ja) 1998-02-24 1999-02-23 受容体活性のモジュレーターとしての受容体由来ペプチド
AU27830/99A AU2783099A (en) 1998-02-24 1999-02-23 Receptor derived peptides as modulators of receptor activity
EP99908383A EP1064015A2 (fr) 1998-02-24 1999-02-23 Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs
CA002322200A CA2322200A1 (fr) 1998-02-24 1999-02-23 Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2893898A 1998-02-24 1998-02-24
US09/028,938 1998-02-24

Publications (2)

Publication Number Publication Date
WO1999042127A2 WO1999042127A2 (fr) 1999-08-26
WO1999042127A3 true WO1999042127A3 (fr) 1999-10-28

Family

ID=21846337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003910 WO1999042127A2 (fr) 1998-02-24 1999-02-23 Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs

Country Status (5)

Country Link
EP (1) EP1064015A2 (fr)
JP (1) JP2002508160A (fr)
AU (1) AU2783099A (fr)
CA (1) CA2322200A1 (fr)
WO (1) WO1999042127A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149906A1 (fr) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Peptide modulateur du récepteur de la thrombopoietine
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
EP2422201B1 (fr) * 2009-04-22 2015-04-22 The Walter and Eliza Hall Institute of Medical Research Structure de la region c terminale de la chaîne alpha du recepteur d'insuline et de la chaîne alpha du recepteur de facteur de croissance de type insuline
UA117801C2 (uk) 2010-11-30 2018-10-10 Дженентек, Інк. Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
WO1995005189A1 (fr) * 1993-08-12 1995-02-23 The Regents Of The University Of California Modulation des antigenes de classe i du complexe majeur d'histocompatibilite (cmh) de l'activite d'un recepteur de surface
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997032899A1 (fr) * 1996-03-08 1997-09-12 Receptron Peptides derives du recepteur, impliques dans la modulation de la reponse a la fixation de ligand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
WO1995005189A1 (fr) * 1993-08-12 1995-02-23 The Regents Of The University Of California Modulation des antigenes de classe i du complexe majeur d'histocompatibilite (cmh) de l'activite d'un recepteur de surface
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997032899A1 (fr) * 1996-03-08 1997-09-12 Receptron Peptides derives du recepteur, impliques dans la modulation de la reponse a la fixation de ligand

Also Published As

Publication number Publication date
EP1064015A2 (fr) 2001-01-03
JP2002508160A (ja) 2002-03-19
CA2322200A1 (fr) 1999-08-26
AU2783099A (en) 1999-09-06
WO1999042127A2 (fr) 1999-08-26

Similar Documents

Publication Publication Date Title
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP1053255A4 (fr) STRUCTURES TRIDIMENSIONNELLES ET MODELES DE RECEPTEURS Fc, ET LEURS UTILISATIONS
EP1270585A4 (fr) Derive peptidique
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
CA2290485A1 (fr) Procede de production de proteines non immunogenes
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
ATE324441T1 (de) Htk-ligand
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
WO1999042127A3 (fr) Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs
DE69820449D1 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
ATE301714T1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
Reissmann et al. Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D-and L-phenylalanine
FI971427A0 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
WO1992016623A3 (fr) Recepteur pour peptide analogue a la bombesine
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE69834929D1 (de) Verwendung eines organspezifischen ernährungmittels
AU7649098A (en) Syndecan interacting proteins and the use thereof
DE69631624D1 (de) Antikörper gegen menschliches restrictin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2322200

Country of ref document: CA

Ref country code: CA

Ref document number: 2322200

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 532141

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999908383

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999908383

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999908383

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载